Kezar Life Sciences, Inc. — Director's Dealing 2023

Jul 26, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kezar Life Sciences, Inc. (KZR)
CIK: 0001645666
Period of Report: 2023-07-24

Reporting Person: Garner Elizabeth (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-07-24	Stock Option (Right to Buy)	$3.03	D	17793	Disposed	2029-12-17	Common Stock (17793)	Direct
2023-07-24	Stock Option (Right to Buy)	$2.28	A	17793	Acquired	2029-12-17	Common Stock (17793)	Direct
2023-07-24	Stock Option (Right to Buy)	$5.60	D	8896	Disposed	2030-06-23	Common Stock (8896)	Direct
2023-07-24	Stock Option (Right to Buy)	$2.28	A	8896	Acquired	2030-06-23	Common Stock (8896)	Direct
2023-07-24	Stock Option (Right to Buy)	$5.59	D	26000	Disposed	2031-06-27	Common Stock (26000)	Direct
2023-07-24	Stock Option (Right to Buy)	$2.28	A	26000	Acquired	2031-06-27	Common Stock (26000)	Direct
2023-07-24	Stock Option (Right to Buy)	$4.80	D	26000	Disposed	2032-06-15	Common Stock (26000)	Direct
2023-07-24	Stock Option (Right to Buy)	$2.28	A	26000	Acquired	2032-06-15	Common Stock (26000)	Direct

Footnotes

F1: Fully vested and exercisable.

F2: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.